Until now, more than 10 different ALK fusion partners have been discovered in nonsmall cell lung cancer (NSCLC): EML4, KIF5B, KLC1, TFG, TPR, HIP1, STRN, DCTN1, SQSTM1 and BIRC 6, among others [1, 2]. We report here a novel ALK fusion partner in a NSCLC patient who responded well to the ALK inhibitor crizotinib.
We report a novel ALK fusion partner in a NSCLC patient who responded well to the ALK inhibitor crizotinib http://ow.ly/7O6f309KyFb
Conflict of interest: None declared.
- Received November 2, 2016.
- Accepted January 3, 2017.
- Copyright ©ERS 2017